Editorial
Copyright ©2011 Baishideng Publishing Group Co.
World J Stem Cells. Apr 26, 2011; 3(4): 25-33
Published online Apr 26, 2011. doi: 10.4252/wjsc.v3.i4.25
Table 4 Clincial trials using adipose-derived stromal cell
Clinical trials with ADSCDesignResultsRef
Maxillary reconstructionAutologous ADSC case reportSuccess{Mesimaki, 2009 #480}
Cryptoglandular origin fistula with or without Crohn’s diseaseAutologous ADSC phase I/II intra-tissueADSCs more effective (P = 0.001). Recurrence rate with ADSC = 17.6%{Garcia-Olmo, 2008 #451; Garcia-Olmo, 2009 #449}
Autologous ADSCOngoing, not recruitingNCT00115466*
Phase II, 2 arms (fibrin glue, fibrin glue + ADSC)
Crohn’s disease fistulaAutologous ADSC, phase I and IIPhase I, completeNCT00992485*
Phase II recruitingNCT01011244*
Autologous ADSC, phase IPhase I/II recruitingNCT01157650*
Allogenic ADSC: phase I/IIrecruitingNCT00999115*
20 × 106 then 40 × 106
Complex Perianal Fistulas not associated to Crohn’s diseaseAutologous ADSC, phase III three arms (fibrine, ADSC, fibrin glue + ADSC; 20 × 106 then 40 × 106 when no effect)Completed (214 enrolled patients)NCT00475410*
Long term safetyRecruitingNCT01020825*
Depressed ScarAutologous ADSC predifferentiated towards adipocyte, phase II, IIICompleteNCT00992147*
Chronic critical limb IschemiaAutologous ADSC, phase IRecruitingNCT01211028*
im 100 × 106
Chronic critical limb Ischemia in diabetic patientsAutologous ADSC, phase I/IIRecruitingNCT01079403*
iv administration
Fecal incontinenceAutologous ADSC, phase IRecruitingNCT01011686*
GVHDAutologous ADSC4/5 alive (after a median follow-up of 40 mo){Fang, 2007 #469}
iv 106/kg
Autologous ADSCRecruitingNCT01222039
Three arms no administration, iv 106/kg or 3 × 106/kg
Secondary Progressive Multiple SclerosisAutologous ADSC phase I/IIRecruitingNCT01056471*
3 arms (iv 106 and 4 × 106/kg against no intervention)